Incyte Earnings Day: Defensive Options, a Rising Short Position, and a 2028 Clock

Incyte Corporation reports Q3 results today with the stock down 2% on Monday to $113.31, giving back ground after last week's partial recovery from an 8.5% monthly decline. The setup is more cautious than the share price alone suggests: options positioning has turned defensive, short interest has rebuilt steadily through October, and the central question overhanging the quarter is whether Jakafi and Opzelura can demonstrate enough momentum to give investors confidence ahead of the 2028 patent cliff.

Options traders have been the most explicit about their anxiety. The put/call ratio closed Monday at 1.88, above its 20-day average of 1.77 and roughly one standard deviation elevated. That is a meaningful softening from the peak defensiveness described in last week's note, when the PCR had reached 1.94 and the stock was at $116.62. Since then, the stock has slipped to $113.31 and the ratio has eased only marginally, suggesting the hedging demand is sticky rather than a brief spike. The full 52-week range runs from 0.44 to 2.52, so the reading is firmly in the upper half without being at extremes. Peers are mostly firmer on the session: AMGN added 1.2%, GILD rose 1.7%, and ABBV edged up 0.4%, while INCY fell, underscoring the stock-specific caution.

Short interest has climbed roughly 17% over the past month to about 5.3% of the free float, rebuilding from September lows where it had dipped to around 9 million shares. The borrow market, however, remains completely relaxed. Availability is near 2,900%, meaning there is far more stock available to lend than is currently borrowed, and borrowing costs at 0.46% are near their 12-month floor despite a 22% uptick on the week. The rising short position is a conviction trade, not a squeeze-driven squeeze, and availability at these levels means new shorts face no friction.

Analyst opinion ahead of the print is broadly constructive but with important divisions. TD Cowen raised its target to $140 on Tuesday, maintaining a Buy, while Stifel lifted its target earlier in October to $157. Against that, RBC Capital rates the stock at Sector Perform with a $114 target, effectively at current prices, and Truist Securities holds at $115. The consensus mean target is $129.54, roughly 14% above Monday's close. The core bull case rests on Opzelura approaching $900 million in annual sales and Jakafi holding its ground in myelofibrosis and polycythemia vera, plus early-stage promise from INCB161734 in KRAS G12D. Felix J. Baker, whose Schedule 13D filing marks him as an activist on Incyte's register and who held approximately 15.6% as last disclosed in May, remains the stock's largest declared investor. That stake is "as last disclosed" and positions around the 5% threshold can move without a further filing.

Medicaid reimbursement data from the Centers for Medicare and Medicaid Services adds a supporting data point, though none of Incyte's alt data series have been measured as a lead indicator for its reported figures. Medicaid dollars reimbursed for Incyte's drugs have risen for three consecutive quarters, with the most recent quarterly reading at roughly $96 million. Medicaid units reimbursed were up 26% on Q1 last year. These figures cover the first quarter of 2026 and confirm continued prescription volume growth in the government payer channel, without constituting a forecast of today's print.

The quarter's report is ultimately a test of whether Opzelura's dermatology trajectory and the Jakafi base together generate enough near-term earnings momentum to keep the stock at a premium to the patent-cliff discount that bears argue is already warranted.